Ask AI
ProCE Banner Activity

Emerging Immunotherapy Combinations in Upper GI Cancers

Clinical Thought

This activity features expert faculty insights from a recent webinar exploring emerging opportunities for novel immunotherapy combinations in upper gastrointestinal cancers. 

Released: December 31, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals caring for patients with upper gastrointestinal cancers

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appraise new efficacy and safety data on novel immunotherapy combinations in advanced upper gastrointestinal cancers and the potential implications for clinical practice

  • Evaluate how the mechanism of action, molecular targets, and design of investigational immunotherapy combinations impact safety and efficacy in patients with advanced upper gastrointestinal cancers

  • Plan first-line treatments that incorporate approved or investigational immunotherapy combinations available through clinical trials to optimize outcomes for patients with advanced upper gastrointestinal cancers

  • Implement strategies to support equitable access to novel immunotherapy combinations in underserved patient populations with advanced upper gastrointestinal cancers

Disclosure

Primary Author

Samuel J. Klempner, MD, FASCO: consultant/advisor: Astellas, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Elevation Oncology, EsoBiotec, Gilead, I-Mab, Merck, Mersana, Natera, Novartis, Signet, Taiho; researcher (paid to institution): Arcus, AstraZeneca, I-Mab, Mersana, Parabilis.

Elizabeth Smyth, MD, FRCP: consultant/advisor/speaker: Amgen, Astellas, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Merck, Novartis, Pfizer, Jazz, Zymeworks.

Raghav Sundar, MD, PhD: consultant/advisor/speaker: Astellas, AstraZeneca, BeiGene, Daiichi Sankyo/Lilly, DKSH, Ipsen, Sanofi; royalties or patent beneficiary: Auristone, Paxmon.